Physician profile
William Skinner
NPI 1447337860
$311,780.70
in general payments reported to CMS, 2019-2025
61 companies · $2,450 in 2025
The $2,450 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94K · 2020: $51K · 2021: $75K · 2022: $44K · 2023: $13K · 2024: $32K · 2025: $2,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $24K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $8,878 · Travel and Lodging: $1,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $23,540.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,070.50 |
| Food and Beverage | $8,877.82 |
| Travel and Lodging | $1,945.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $91,867.36 | 2019-2024 | Xarelto |
| Amgen INC. | $82,845.92 | 2019-2023 | Repatha |
| Esperion Therapeutics, INC. | $66,885.04 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $27,582.64 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $26,825.17 | 2023-2024 | Inpefa |
| Medtronic Vascular, INC. | $2,951.86 | 2019-2020 | |
| Boston Scientific Corporation | $1,149.88 | 2021-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,006.74 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $812.01 | 2021-2025 | Verquvo, Capvaxive, Winrevair |
| Actelion Pharmaceuticals US, INC. | $780.22 | 2019-2024 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals Lp | $734.09 | 2019-2025 | Brilinta, Farxiga, Wainua |
| Pfizer INC. | $678.29 | 2019-2025 | |
| Medtronic, INC. | $673.77 | 2021-2025 | Symplicity G3, Onyx Frontier, Corevalve Evolut R |
| Sanofi-Aventis U.S. LLC | $653.63 | 2019-2024 | |
| Abbott Laboratories | $510.98 | 2020-2025 | Navitor, Mitraclip, Pressurewire |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Skinner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.